Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CLAM trial regimen shown safe, effective for r/r AML

Key clinical point: Clofarabine, cytarabine, and mitoxantrone showed promise for refractory/relapsed acute myeloid leukemia.

Major finding: The overall response rate after the first cycle of CLAM was 90.4%.

Study details: A phase 2 study of treatment effects on 52 patients with refractory/relapsed acute myeloid leukemia.

Disclosures: No disclosures or conflicts of interest were reported.

Citation:

Gill H et al. Cancer Med. 2020 Mar 20. doi:10.1002/cam4.2865.